shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    Rigorous Evaluation of Primary and Secondary Overdose Prevention Activities Among Populations Disproportionately Affected by Overdose

    RFA-CE-25-149

    Candis M. Hunter, PhD, MSPH, REHS

    Opening date 3 May 2024, 12:00AM

    Closing date N/A

    Funding Opportunity Number: RFA-CE-25-149

    Opportunity Category: Discretionary

    Expected Number of Awards: 6

    CFDA Number(s): 93.136 -- Injury Prevention and Control Research and State and Community Based Programs

    Cost Sharing or Matching Requirement: No

    Posted Date: May 03, 2024 12:00:00 AM EDT

    Closing Date: N/A

    Estimated Total Program Funding: 4200000

    Award Ceiling: $700000

    Eligible Applicants: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Independent school districts,City or township governments,Public housing authorities/Indian housing authorities,Special district governments,For profit organizations other than small businesses,Native American tribal governments (Federally recognized),Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility",Others (see text field entitled "Additional Information on Eligibility" for clarification),Native American tribal organizations (other than Federally recognized tribal governments),Small businesses,Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education,County governments,Public and State controlled institutions of higher education,Private institutions of higher education,State governments

    Additional Information on Eligibility: The following types of Higher Education Institutions are always encouraged to apply for CDC support as Public or Private Institutions of Higher Education:Hispanic-serving InstitutionsHistorically Black Colleges and Universities (HBCUs)Tribally Controlled Colleges and Universities (TCCUs)Alaska Native and Native Hawaiian Serving InstitutionsNonprofits (Other than Institutions of Higher Education):Nonprofits (Other than Institutions of Higher Education)Other:Faith-based or Community-based OrganizationsRegional OrganizationsBona Fide Agents: A Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If applying as a bona fide agent of a state or local government, a legal, binding agreement from the state or local government as documentation of the status is required. Attach with "Other Attachment Forms."Federally Funded Research and Development Centers (FFRDCs): FFRDCs are operated, managed, and/or administered by a university or consortium of universities, other not-for-profit or nonprofit organization, or an industrial firm, as an autonomous organization or as an identifiable separate operating unit of a parent organization. A FFRDC meets some special long-term research or development need which cannot be met as effectively by an agency's existing in-house or contractor resources. FFRDC's enable agencies to use private sector resources to accomplish tasks that are integral to the mission and operation of the sponsoring agency. For more information on FFRDCs, go to https://gov.ecfr.io/cgi-bin/searchECFR.

    Description: The Centers for Disease Control and Prevention’s (CDC) National Center for Injury Prevention and Control (NCIPC, Injury Center) is soliciting investigator-initiated research to develop, implement, and rigorously evaluate prevention strategies among populations or communities experiencing disproportionate burden of drug overdose or those who are at greater risk of exposure to drug use and experiencing adverse outcomes related to drug use due to social determinants of health. Funding can be used to develop, implement, and rigorously evaluate strategies that (1) prevent adverse outcomes related to drug use among those not yet engaged in drug use (i.e., primary prevention) or (2) reduce adverse outcomes among those already engaged in drug use by linking and retaining them in care (i.e., secondary prevention). The proposed research should rigorously evaluate either primary or secondary prevention strategies, on reducing rates of at least two primary outcomes from this list: nonfatal overdose, fatal overdose, substance use disorders involving federally illicit drugs or misuse of prescription medications, drug use, or initiation of drug use particularly among youth.

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept